Jul 10,2018

First-Year Results from Medtronic and UnitedHealthcare Value-Based Relationship Demonstrate Cost-Savings and Reduced Hospital Admissions

The first-year results reported today are from the measurement period of July 2016 through June 2017 and do not include use of Medtronic's newest insulin pump, the MiniMed 670G system, which was commercially launched at the end of the measurement period. both real-world and clinical trial data on the MiniMed 670G system demonstrate significantly improved Time in Range (the percentage of time spent in the optimal glycemic range of 70-180 mg/dL), A1C (a marker of blood sugar control over time) and Quality of Life for people using the system instead of MDI to manage their Type 1 diabetes.

PRODUCT

#insulin pump

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 17,2018

Nemaura Places SugarBEAT® Manufacturer Order for UK Commercial Launch

Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced it has placed an initial order with its designated UK-based contract manufacturer for 12,500 sugarBEAT® rechargeable transmitters, which will be supplemented with approximately 100,000 skin-patches per month, also manufactured in the UK, in preparation for the anticipated sugarBEAT® product launch in the coming months.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 31,2018

Nemaura Initiates US FDA Studies, and Reports Positive Interim Data from Home-Use Portion of Study

Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® announced it has initiated the first of a number of planned studies in support of a submission to the U.S Food & Drug Administration for approval of its sugarBEAT® product, and further announced positive interim results from the home-use portion of this initial study. The results analysed 121 matched pair points between the BGM and sugarBEAT®, and indicated 84.3% of the data points had an overall MARD (Mean absolute relative deviation) of 10.63%, and an overall nominal MARD of 16.3% (compared with 14.8%, 16.3% and 18% for Eversense, Dexcom G5 and Abbott Libre Pro respectively*).

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 07,2018

Senseonics Begins U.S. Commercialization of Eversense Continuous Glucose Monitoring System With First Shipment, First Users and First Policy Coverage

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that the Eversense® CGM System is now available at trained clinics across the U.S. and physicians have begun sensor placements with patients. Concurrently, the company reported that its first commercial payer, Horizon Blue Cross Blue Shield of New Jersey and Horizon Healthcare of New Jersey, has added coverage of the Eversense System to its Medical Policy.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 10,2018

Rimidi Partners with Dexcom for the Launch of Their Data Platform

Rimidi, a provider of digital health solutions to improve the management of chronic diseases, is an inaugural data partner in Dexcom’s newly launched open data platform. Dexcom users will be able to share their data with their healthcare provider through Rimidi and Rimidi makes that data available within the clinician’s workflow in order to drive treatment decisions that address individual patient needs.

COLLABORATION PARTNERSHIP

#connected device

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 05,2018

Livongo Health to offer Freestyle Libre Pro CGM patch to some users

Livongo Health, the digital chronic disease management company founded by former Allscripts CEO Glen Tullman, announced today that it will be the first United States enterprise diabetes management company to bring Abbott’s Freestyle Libre Pro continuous glucose monitoring patch to its customers. This marks the first time Livongo has incorporated a CGM of any kind, as opposed to fingerprick glucometers.

COLLABORATION PARTNERSHIP

#product & service

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 12,2018

Nemaura Reports Positive Interim Data from Clinic Portion of SugarBEAT® FDA Clinical Trial

The interim results consisted of 25 patients, split approximately equally between Type I and Type II diabetics. 9,371 data points were analysed in total, consisting of 4,630 and 4,741 paired data points analysed using 1-point and 2-point calibration respectively. The MARD (Mean Absolute Relative Deviation, @ 30%/30mg/dL) for the 1-point calibration was 12.19% (80% of all data), and for the 2-point calibration the MARD was 10.65% (88% of all data)). The results are in line with the company’s expectations, and compare favorably with competitor products.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 18,2018

Nemaura Signs Letter of Intent for SugarBEAT® Commercial Launch in Qatar

Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible Continuous Glucose Monitor (CGM) for use by persons with diabetes and pre-diabetics, today announced that it has signed a non-binding letter of intent for an exclusive licensing agreement with Al-Danah Medical Co for the commercial launch of sugarBEAT® in Qatar. A final binding license agreement between Nemaura and Al-Danah is scheduled for completion by November 16, 2018 in readiness for anticipated 2019 Qatar product launch.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 25,2018

Nemaura Reports Positive Zero Finger-Stick Calibration Data for SugarBEAT® Continuous Glucose Monitor

Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible Continuous Glucose Monitor (CGM) for use by people with diabetes and pre-diabetics, today announced data indicating sugarBEAT® could potentially be used as an adjunctive CGM without the need for finger-stick calibration.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 22,2018

Senseonics Announces Aetna’s Positive Coverage Decision for Eversense

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that Aetna, the third largest commercial health plan provider in the United States, is providing coverage for Eversense, effective immediately.

COLLABORATION PARTNERSHIP

#insurance

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM